ClinicalTrials.gg
CompletedNCT02449044Updated Jan 21, 2016Results posted

International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

A Phase 3 interventional study of Tolvaptan in Hyponatremia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-21.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.

Enrollment
6th of 20
111 · median 55
Started
2004
the only one that year
Phase 3
9 of 20
none open now
Registered
17th of 20
by date
Lead sponsor
8 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 6th largest by enrollment, is the only one that started in 2004, is one of 9 in phase 3, and was the 17th registered.

Hyponatremia

164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.

Browse Hyponatremia studies →

Open to participants now

None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing tolvaptan in Hyponatremia as a file.
02

Study summary

This study will assess the safety of long-term tolvaptan use in patients previously enrolled in shorter-term Phase 3 studies and gather information on the natural history of hyponatremia in the context of tolvaptan therapy and underlying disease states.

03

Conditions studied

  • Hyponatremia

Browse trials for

Keywords

  • Hyponatremia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to 18 years.
  2. Ability to provide or assent.
  3. Prior successful participation in a tolvaptan hyponatremia trial termination with evidence of continued need or desire for therapy.

Exclusion criteria

Exclusion Criteria:

  • A current medical condition where long-term treatment with an aquaretic agent may present an undue risk to the patient.
  • Hyponatremia which is acute, reversible, artifactual or due to conditions not associated with vasopressin excess or likely to respond to aquaretic therapy.
  • Hyponatremia due to reversible medical condition or therapy
  • Conditions associated with an independent imminent risk of morbidity and mortality
  • Conditions which confound the assessment of endpoints.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.

    Drug: Tolvaptan

Interventions

06

What researchers measure

Primary outcomes

  1. Participants With Adverse Events (AEs)

    A TEAE was an AE that began after the first injection or was continuous from Baseline and was defined as any new medical problem, or exacerbation of an existing problem, whether or not it was considered drug-related by the study physician. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-subject hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent the outcomes mentioned above.

    Time frame: Baseline to Post-Week 214 follow-up visit

  2. Participants With Laboratory Values Abnormalities Reported as TEAEs

    The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Any value outside the normal range was flagged for the attention of the study physician who was to indicate whether the value was clinically significant for identifying laboratory values of potential clinical relevance. Participants noted with abnormal laboratory values are reported below.

    Time frame: Baseline to Post-Week 214 follow-up visit

  3. Participants With Electrocardiogram (ECG) Related Abnormalities Reported as TEAEs

    The ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in HR outliers, PR outliers, QRS outliers, QT, QTcB, QTcF that were identified based on pre-defined criteria. Some of the pre-defined criteria for identifying ECG measurements of potential clinical relevance included: For QTcB and QTcF: baseline mean of QTcB and QTcF interval was new onset \>500 msec, 30 - 60 msec, \>60 msec; For QT: new onset \>500 msec; For QRS outliers: \>=25% change from baseline when QRS \>100 msec; PR outliers: \>=25% change from baseline when PR\>200 msec; HR outliers: 25% decrease from baseline and HR \<50 bpm or 25% increase from baseline and HR \>100 bpm. New onset (\>500 msec) in QT, QTcB, or QTcF means a participant who attained a value \>500 msec during treatment period but not at each baseline visit. The ECG-related abnormalities are reported as TEAEs are mentioned below.

    Time frame: Baseline to Post-Week 214 follow-up visit

  4. Participants With Vital Signs Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)

    The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Criteria for identifying vital signs of potential clinical relevance included: Heart rate, supine: \>= 120 beats per minute (bpm) + increase of ≥15 bpm from Baseline and \<=50 bpm + decrease of \>= 15 bpm; Diastolic Blood Pressure, Supine: \>=105 mmHg + increase of \>=15 mmHg and \<=50 mmHg + decrease of \>=15 mmHg; Systolic Blood Pressure, Supine: \>=180 mmHg + increase of \>=20 mmHg and \<= 90 mmHg + decrease of \>=20 mmHg; Temperature (degree C): Increase of \>=1.1 to \>=38.3C. The vital sign abnormalities were reported as TEAEs are mentioned below.

    Time frame: Baseline to Post-Week 214 follow-up visit

  5. Participants With Body Weight Abnormalities Reported as TEAEs

    The body weight evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Every effort was made to ensure that body weight measurements were performed in a reproducible and consistent manner. The pre-defined criteria was change of ≥7% in body weight for both male and female. Participants were to wear the same type of clothes at each measurement, preferably a gown and no shoes. All body weight measurements were to have been taken post-void.

    Time frame: Baseline to Post-Week 214 follow-up visit

Secondary outcomes

  1. Mean Change From Baseline in Serum Sodium Measurements

    Sodium measurements obtained at designated intervals were compared to each participant's Baseline sodium level at the beginning of placebo-controlled therapy in their original trial and from Baseline on initiation of therapy in the open-label trial.

    Time frame: Baseline of parent trial to Week 214

  2. Change From Baseline in Percentage of Participants With Severe Hyponatremia

    Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.

    Time frame: Baseline to Week 214

  3. Change From Baseline in Percentage of Participants With Mild Hyponatremia

    Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.

    Time frame: Baseline to Week 214

  4. Change From Baseline in Percentage of Participants With Normal Sodium Levels

    Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.

    Time frame: Baseline to Week 214

  5. Percentage of Participants Requiring Prescription of Fluid Restriction

    Percentage of participants requiring prescription of fluid restriction for the express purpose of treating hyponatremia during each period of the trial. Assessed descriptively at each visit.

    Time frame: Baseline to Post-Week 214 follow-up visit

  6. Number of Participants Requiring Prescription of Hypertonic Saline

    Percentage of participants requiring prescription of hypertonic saline for the express purpose of treating hyponatremia during each period of the trial, assessed descriptively at each visit.

    Time frame: Baseline to Post-Week 214 follow-up visit

  7. Percentage of Participants Requiring Prescription of Other Medicines

    Percentage of participants requiring prescription of other medicines for the express purpose of treating hyponatremia during each period of the trial, assessed descriptively at each visit.

    Time frame: Baseline to Post-Week 214 follow-up visit

  8. Mean Change From Baseline in Body Weight by Visit for Those Participants Who Had Clinical Evidence of Hypervolemia at Baseline

    Body weight at each visit (assessed only for those with clinical evidence of hypervolemia at Baseline) and was summarized using descriptive statistics.

    Time frame: Baseline to Week 214

  9. Mean Change From Baseline in SF-12 (Health Survey) Physical Component Summary (PCS)

    The PCS assess the physical and mental dimensions of health-related quality of life. The PCS is equal to the sum of the items of endurance activities, strength activities, gross coordination activities, and fine coordination activities. The PCS is a computed score with weighted function based on the 12 questions from the 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health) of the SF-12v1 questionnaire per instructions by the scale's publisher. The scale ranges from 0 to 100 with 0 representing the lowest level of health and 100 indicating the highest level of health.

    Time frame: Baseline to Week 214

  10. Mean Change From Baseline in SF-12 (Health Survey) Mental Component Summary (MCS)

    The MCS assess the physical and mental dimensions of health-related quality of life. The MCS is equal to the sum of the items of concentration activities, calculating activities, language activities, and memory activities. The MCS is a computed score with weighted function based on the 12 questions from the 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health) of the SF-12v1 questionnaire per instructions by the scale's publisher. The scale ranges from 0 to 100 with 0 representing the lowest level of health and 100 indicating the highest level of health.

    Time frame: Baseline to Week 214

  11. Change From Baseline in the Hyponatremia Disease-specific Survey

    Analysis of individual items of Hyponatremia Disease-specific Survey was not conducted, because the analysis of Hyponatremia Disease-specific Survey was focused on the PCS and MCS summary scores since these 2 scores were developed. Subgroup analyses of Hyponatremia Disease-specific Survey were also not conducted.

    Time frame: Baseline to Week 214

07

Results

Posted Jan 21, 2016

Participant flow

The trial was conducted in 111 enrolled participants at 33 trial centers. This is an extension study of trials NCT00072683 and NCT00201994. Approximately 50% participants may have been on tolvaptan previously, there was a minimum 7-day period off treatment between trials.

Participant flow — Overall Study
MilestoneTolvaptan
Started111
Completed47
Not completed64
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject13
Withdrew: Adverse event30
Withdrew: Met withdrawal criteria7
Withdrew: Physician decision9
Withdrew: Sponsor discontinued trial3

Outcome measures

PrimaryParticipants With Adverse Events (AEs)

A TEAE was an AE that began after the first injection or was continuous from Baseline and was defined as any new medical problem, or exacerbation of an existing problem, whether or not it was considered drug-related by the study physician. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-subject hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent the outcomes mentioned above.

Time frame:
Baseline to Post-Week 214 follow-up visit
Reported as:
Number · participants
Participants With Adverse Events (AEs)
participantsTolvaptan
Participants with TEAEs105
Participants with serious TEAEs76
Participants with severe TEAEs73
Participants discontinued IMP due to TEAE19
Participants discontinued IMP due to TEAE/death28
Deaths19
PrimaryParticipants With Laboratory Values Abnormalities Reported as TEAEs

The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Any value outside the normal range was flagged for the attention of the study physician who was to indicate whether the value was clinically significant for identifying laboratory values of potential clinical relevance. Participants noted with abnormal laboratory values are reported below.

Time frame:
Baseline to Post-Week 214 follow-up visit
Reported as:
Number · participants
Participants With Laboratory Values Abnormalities Reported as TEAEs
participantsTolvaptan
Serum Chemistry-Blood creatinine increased4
Serum Chemistry-Blood potassium increased4
Serum Chemistry-Blood glucose increased3
Serum Chemistry-Blood potassium decreased3
SerumChemistry-Aspartate aminotransferaseincreased2
Serum Chemistry-Blood cholesterol increased3
Serum Chemistry-Blood sodium increased2
Serum Chemistry-Hepatic enzyme increased2
Serum Chemistry-Oxygen saturation decreased2
Serum Chemistry-Hyperglycaemia5
Serum Chemistry-Hyperkalaemia7
Serum Chemistry-Hyperlipidaemia4
Serum Chemistry-Hypernatraemia4
Serum Chemistry-Hyperuricaemia3
Serum Chemistry-Hypoglycaemia5
Serum Chemistry-Hypokalaemia14
Serum Chemistry-Hypomagnesaemia3
Serum Chemistry-Hypoatraemia25
Hematology-Anemia20
Hematology-Thrombocytopenia2
Hematology-International normalized ratioincreased4
Hematology-White blood cell count increased2
PrimaryParticipants With Electrocardiogram (ECG) Related Abnormalities Reported as TEAEs

The ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in HR outliers, PR outliers, QRS outliers, QT, QTcB, QTcF that were identified based on pre-defined criteria. Some of the pre-defined criteria for identifying ECG measurements of potential clinical relevance included: For QTcB and QTcF: baseline mean of QTcB and QTcF interval was new onset \>500 msec, 30 - 60 msec, \>60 msec; For QT: new onset \>500 msec; For QRS outliers: \>=25% change from baseline when QRS \>100 msec; PR outliers: \>=25% change from baseline when PR\>200 msec; HR outliers: 25% decrease from baseline and HR \<50 bpm or 25% increase from baseline and HR \>100 bpm. New onset (\>500 msec) in QT, QTcB, or QTcF means a participant who attained a value \>500 msec during treatment period but not at each baseline visit. The ECG-related abnormalities are reported as TEAEs are mentioned below.

Time frame:
Baseline to Post-Week 214 follow-up visit
Reported as:
Number · participants
Participants With Electrocardiogram (ECG) Related Abnormalities Reported as TEAEs
participantsTolvaptan
Atrial fibrillation6
Tachycardia4
Atrial tachycardia3
First degree atrioventricular block2
Bradycardia2
Sinus tachycardia2
Ventricular tachycardia2
Left bundle branch block1
Tachyarrhythmia1
Ventricular arrhythmia1
Atrial flutter1
ECG ST segment depression1
Arrhythmia1
PrimaryParticipants With Vital Signs Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)

The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Criteria for identifying vital signs of potential clinical relevance included: Heart rate, supine: \>= 120 beats per minute (bpm) + increase of ≥15 bpm from Baseline and \<=50 bpm + decrease of \>= 15 bpm; Diastolic Blood Pressure, Supine: \>=105 mmHg + increase of \>=15 mmHg and \<=50 mmHg + decrease of \>=15 mmHg; Systolic Blood Pressure, Supine: \>=180 mmHg + increase of \>=20 mmHg and \<= 90 mmHg + decrease of \>=20 mmHg; Temperature (degree C): Increase of \>=1.1 to \>=38.3C. The vital sign abnormalities were reported as TEAEs are mentioned below.

Time frame:
Baseline to Post-Week 214 follow-up visit
Reported as:
Number · participants
Participants With Vital Signs Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)
participantsTolvaptan
Hypotension13
Hypertension8
Pyrexia6
Increased body temperature3
Palpitations2
Increased central venous pressure2
Increased venous pressure1
Orthostatic hypotension1
Hypertensive crisis1
Decreased orthostatic blood pressure1
Increased weight5
Decreased weight1
PrimaryParticipants With Body Weight Abnormalities Reported as TEAEs

The body weight evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Every effort was made to ensure that body weight measurements were performed in a reproducible and consistent manner. The pre-defined criteria was change of ≥7% in body weight for both male and female. Participants were to wear the same type of clothes at each measurement, preferably a gown and no shoes. All body weight measurements were to have been taken post-void.

Time frame:
Baseline to Post-Week 214 follow-up visit
Reported as:
Number · participants
Participants With Body Weight Abnormalities Reported as TEAEs
participantsTolvaptan
Increased weight5
Decreased weight1
SecondaryMean Change From Baseline in Serum Sodium Measurements

Sodium measurements obtained at designated intervals were compared to each participant's Baseline sodium level at the beginning of placebo-controlled therapy in their original trial and from Baseline on initiation of therapy in the open-label trial.

Time frame:
Baseline of parent trial to Week 214
Reported as:
Mean · mEq/L
Mean Change From Baseline in Serum Sodium Measurements
mEq/LTolvaptan
Day 1 post-dose (N= 99)2.2 ± 3.3
Day 14 (N= 110)5.2 ± 5.5
Day 31 (N= 110)5.0 ± 4.8
Week 10 (N= 110)5.0 ± 5.1
Week 18 (N= 110)4.6 ± 5.4
Week 26 (N= 110)4.2 ± 5.7
Week 34 (N= 110)4.7 ± 5.9
Week 42 (N= 110)5.2 ± 5.6
Week 50 (N= 110)5.0 ± 5.9
Week 58 (N= 110)5.0 ± 5.9
Week 70 (N= 110)4.8 ± 5.8
Week 82 (N= 110)4.8 ± 5.7
Week 94 (N= 110)5.1 ± 5.8
Week 106 (N= 110)5.0 ± 6.0
Week 118 (N= 110)4.8 ± 5.9
Week 130 (N= 110)4.9 ± 6.0
Week 142 (N= 110)5.2 ± 5.9
Week 154 (N= 110)5.2 ± 5.9
Week 166 (N= 110)4.9 ± 5.8
Week 178 (N= 110)4.8 ± 5.9
Week 190 (N= 110)5.1 ± 6.1
Week 202 (N= 110)5.0 ± 5.9
Week 214 (N= 110)5.0 ± 5.9
Statistical analysis
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Day 1.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Day 14.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Day 31.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 10.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 18.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 26.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 34.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 42.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 50.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 58.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 70.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 82.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 94.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 106.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 118.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 130.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 142.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 154.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 166.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 178.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 190.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 202.)
  • Tolvaptan · Student's t-test · p = <0.0001 (This was the p-value for analysis at Week 214.)
SecondaryChange From Baseline in Percentage of Participants With Severe Hyponatremia

Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.

Time frame:
Baseline to Week 214
Reported as:
Number · percentage of participants
Change From Baseline in Percentage of Participants With Severe Hyponatremia
percentage of participantsTolvaptan
Day 1 post-dose (N=99)20.2 ± 3.0
Day 31 (N=110)9.1 ± 5.1
Week 10 (N=110)11.8 ± 5.0
Week 18 (N=110)13.6 ± 4.0
Week 26 (N=110)16.4 ± 4.6
Week 34 (N=110)14.5 ± 5.6
Week 42 (N=110)12.7 ± 4.1
Week 50 (N=110)10.9 ± 4.5
Week 58 (N=110)13.6 ± 5.1
Week 70 (N=110)12.7 ± 4.6
Week 82 (N=110)10.9 ± 4.1
Week 94 (N=110)10.9 ± 4.8
Week 106 (N=110)12.7 ± 4.7
Week 118 (N=110)12.7 ± 4.4
Week 130 (N=110)11.8 ± 4.7
Week 142 (N=110)11.8 ± 4.5
Week 154 (N=110)11.8 ± 4.4
Week 166 (N=110)11.8 ± 4.5
Week 178 (N=110)11.8 ± 4.5
Week 190 (N=110)11.8 ± 4.7
Week 202 (N=110)11.8 ± 4.6
Week 214 (N=110)11.8 ± 4.6
SecondaryChange From Baseline in Percentage of Participants With Mild Hyponatremia

Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.

Time frame:
Baseline to Week 214
Reported as:
Number · percentage of participants
Change From Baseline in Percentage of Participants With Mild Hyponatremia
percentage of participantsTolvaptan
Day 1 post-dose (N=99)53.5
Day 31 (N=110)33.6
Week 10 (N=110)28.2
Week 18 (N=110)33.6
Week 26 (N=110)30.9
Week 34 (N=110)26.4
Week 42 (N=110)26.4
Week 50 (N=110)31.8
Week 58 (N=110)26.4
Week 70 (N=110)30.9
Week 82 (N=110)31.8
Week 94 (N=110)28.2
Week 106 (N=110)27.3
Week 118 (N=110)28.2
Week 130 (N=110)29.1
Week 142 (N=110)25.5
Week 154 (N=110)25.5
Week 166 (N=110)30.9
Week 178 (N=110)30.9
Week 190 (N=110)30.9
Week 202 (N=110)30.9
Week 214 (N=110)30.9
SecondaryChange From Baseline in Percentage of Participants With Normal Sodium Levels

Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.

Time frame:
Baseline to Week 214
Reported as:
Number · percentage of participants
Change From Baseline in Percentage of Participants With Normal Sodium Levels
percentage of participantsTolvaptan
Day 1 post-dose (N=99)26.3
Day 31 (N=110)57.3
Week 10 (N=110)60.0
Week 18 (N=110)52.7
Week 26 (N=110)52.7
Week 34 (N=110)59.1
Week 42 (N=110)60.9
Week 50 (N=110)57.3
Week 58 (N=110)60.0
Week 70 (N=110)56.4
Week 82 (N=110)57.3
Week 94 (N=110)60.9
Week 106 (N=110)60.0
Week 118 (N=110)59.1
Week 130 (N=110)59.1
Week 142 (N=110)62.7
Week 154 (N=110)62.7
Week 166 (N=110)57.3
Week 178 (N=110)57.3
Week 190 (N=110)57.3
Week 202 (N=110)58.2
Week 214 (N=110)57.3
SecondaryPercentage of Participants Requiring Prescription of Fluid Restriction

Percentage of participants requiring prescription of fluid restriction for the express purpose of treating hyponatremia during each period of the trial. Assessed descriptively at each visit.

Time frame:
Baseline to Post-Week 214 follow-up visit
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Prescription of Fluid Restriction
percentage of participantsTolvaptan
Mild Hyponatremia (N=76)14.47
Severe Hyponatremia (N=35)5.71
SecondaryNumber of Participants Requiring Prescription of Hypertonic Saline

Percentage of participants requiring prescription of hypertonic saline for the express purpose of treating hyponatremia during each period of the trial, assessed descriptively at each visit.

Time frame:
Baseline to Post-Week 214 follow-up visit
Reported as:
Number · participants
Number of Participants Requiring Prescription of Hypertonic Saline
participantsTolvaptan
Number of Participants Requiring Prescription of Hypertonic Saline2
SecondaryPercentage of Participants Requiring Prescription of Other Medicines

Percentage of participants requiring prescription of other medicines for the express purpose of treating hyponatremia during each period of the trial, assessed descriptively at each visit.

Time frame:
Baseline to Post-Week 214 follow-up visit
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Prescription of Other Medicines
percentage of participantsTolvaptan
Percentage of Participants Requiring Prescription of Other Medicines0
SecondaryMean Change From Baseline in Body Weight by Visit for Those Participants Who Had Clinical Evidence of Hypervolemia at Baseline

Body weight at each visit (assessed only for those with clinical evidence of hypervolemia at Baseline) and was summarized using descriptive statistics.

Time frame:
Baseline to Week 214
Reported as:
Mean · kg
Mean Change From Baseline in Body Weight by Visit for Those Participants Who Had Clinical Evidence of Hypervolemia at Baseline
kgTolvaptan
Day 31 (N= 26)-0.5 ± 4.6
Week 10 (N= 32)-1.1 ± 3.7
Week 18 (N= 27)0.2 ± 3.0
Week 26 (N= 27)0.4 ± 5.4
Week 34 (N= 26)0.5 ± 4.0
Week 42 (N= 24)0.3 ± 4.6
Week 50 (N= 22)1.0 ± 4.7
Week 58 (N= 22)1.7 ± 4.5
Week 70 (N= 18)1.7 ± 5.2
Week 82 (N= 18)2.0 ± 7.0
Week 94 (N= 18)3.0 ± 8.0
Week 106 (N= 15)1.4 ± 8.0
Week 118 (N= 13)2.2 ± 8.1
Week 130 (N= 13)3.0 ± 9.0
Week 142 (N= 12)3.8 ± 8.7
Week 154 (N= 11)2.7 ± 7.9
Week 166 (N= 9)2.9 ± 9.4
Week 178 (N= 7)3.2 ± 8.6
Week 190 (N= 5)-2.4 ± 4.5
Week 202 (N= 2)-7.1 ± 0.4
Week 214 (N= 2)-8.5 ± 1.6
Statistical analysis
  • Tolvaptan · Student's t-test · p = 0.4922 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.1054 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.7656 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.7084 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.5138 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.7175 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3540 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0852 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.1923 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.2335 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.1346 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.5237 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3476 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.2488 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.1598 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.2820 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3743 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3600 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3101 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0269 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0944 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
SecondaryMean Change From Baseline in SF-12 (Health Survey) Physical Component Summary (PCS)

The PCS assess the physical and mental dimensions of health-related quality of life. The PCS is equal to the sum of the items of endurance activities, strength activities, gross coordination activities, and fine coordination activities. The PCS is a computed score with weighted function based on the 12 questions from the 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health) of the SF-12v1 questionnaire per instructions by the scale's publisher. The scale ranges from 0 to 100 with 0 representing the lowest level of health and 100 indicating the highest level of health.

Time frame:
Baseline to Week 214
Reported as:
Mean · Units on a scale
Mean Change From Baseline in SF-12 (Health Survey) Physical Component Summary (PCS)
Units on a scaleTolvaptan
Day 14 (N= 102)1.0 ± 7.3
Day 31 (N= 106)0.4 ± 7.9
Week 10 (N= 106)0.3 ± 8.1
Week 18 (N= 106)0.4 ± 8.1
Week 26 (N= 106)-0.9 ± 9.7
Week 34 (N= 106)-0.3 ± 9.4
Week 42 (N= 106)-1.1 ± 9.4
Week 50 (N= 106)-1.1 ± 9.0
Week 58 (N= 106)-0.9 ± 9.0
Week 70 (N= 106)-1.1 ± 9.1
Week 82 (N= 106)-0.9 ± 8.9
Week 94 (N= 106)-1.6 ± 9.1
Week 106 (N= 106)-1.7 ± 8.4
Week 142 (N= 2)-9.1 ± 10.8
Week 166 (N= 2)4.6 ± 9.7
Week 178 (N= 2)-11.3 ± 2.5
Week 190 (N= 6)-2.2 ± 5.6
Week 202 (N= 1)0.6 ± NA
Week 214 (N= 6)4.0 ± 9.2
Statistical analysis
  • Tolvaptan · Student t-test · p = 0.1739 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.6095 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.6902 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.6340 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3210 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.7787 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.2198 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.1926 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3109 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.2269 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.2749 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0702 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0412 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.4448 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.6233 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.1001 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3739 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3334 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
SecondaryMean Change From Baseline in SF-12 (Health Survey) Mental Component Summary (MCS)

The MCS assess the physical and mental dimensions of health-related quality of life. The MCS is equal to the sum of the items of concentration activities, calculating activities, language activities, and memory activities. The MCS is a computed score with weighted function based on the 12 questions from the 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health) of the SF-12v1 questionnaire per instructions by the scale's publisher. The scale ranges from 0 to 100 with 0 representing the lowest level of health and 100 indicating the highest level of health.

Time frame:
Baseline to Week 214
Reported as:
Mean · Units on a scale
Mean Change From Baseline in SF-12 (Health Survey) Mental Component Summary (MCS)
Units on a scaleTolvaptan
Day 14 (N= 102)-1.0 ± 8.8
Day 31 (N= 106)-1.0 ± 9.6
Week 10 (N= 106)-0.4 ± 9.8
Week 18 (N= 106)-2.0 ± 8.8
Week 26 (N= 106)-1.1 ± 8.8
Week 34 (N= 106)-2.7 ± 9.4
Week 42 (N= 106)-2.1 ± 10.1
Week 50 (N= 106)-1.9 ± 10.4
Week 58 (N= 106)-2.5 ± 11.4
Week 70 (N= 106)-2.6 ± 10.7
Week 82 (N= 106)-2.5 ± 10.5
Week 94 (N= 106)-2.6 ± 10.5
Week 106 (N= 106)-3.7 ± 11.6
Week 142 (N= 2)-11.2 ± 27.6
Week 166 (N= 2)5.0 ± 13.6
Week 178 (N= 2)0.4 ± 4.5
Week 190 (N= 6)-2.8 ± 8.2
Week 202 (N= 1)-0.8 ± NA
Week 214 (N= 6)-0.5 ± 7.8
Statistical analysis
  • Tolvaptan · Student t-test · p = 0.2575 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.2715 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.6860 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0224 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.1871 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0039 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0325 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0631 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0277 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0128 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0164 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0119 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.0013 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.6691 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.6923 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.9292 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.4401 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
  • Tolvaptan · Student's t-test · p = 0.3609 (Descriptive use only, no statistical adjustments for multiplicity were planned.)
SecondaryChange From Baseline in the Hyponatremia Disease-specific Survey

Analysis of individual items of Hyponatremia Disease-specific Survey was not conducted, because the analysis of Hyponatremia Disease-specific Survey was focused on the PCS and MCS summary scores since these 2 scores were developed. Subgroup analyses of Hyponatremia Disease-specific Survey were also not conducted.

Time frame:
Baseline to Week 214

No measurements were reported for this outcome.

Adverse events

Collected over AEs are reported from the signing of the informed consent until the follow-up visit (+7 days) after the last dose of study drug as scheduled or as an early termination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan—76/111 (68.5%)86/111 (77.5%)
Most frequent serious events
Showing 10 of 160
Most frequent serious events
EventTolvaptan
PneumoniaInfections and infestations10/111
HyponatraemiaMetabolism and nutrition disorders10/111
Cardiac failureCardiac disorders7/111
Cardiac failure congestiveCardiac disorders7/111
AscitesGastrointestinal disorders5/111
Gastrointestinal haemorrhageGastrointestinal disorders5/111
Chest painGeneral disorders5/111
EncephalopathyNervous system disorders5/111
AnemiaBlood and lymphatic system disorders4/111
Renal failureRenal and urinary disorders4/111
Most frequent other events
Showing 10 of 45
Most frequent other events
EventTolvaptan
Oedema peripheralGeneral disorders25/111
DiarrhoeaGastrointestinal disorders20/111
NauseaGastrointestinal disorders18/111
Urinary tract infectionInfections and infestations18/111
HyponatraemiaMetabolism and nutrition disorders17/111
AnaemiaBlood and lymphatic system disorders16/111
FatigueGeneral disorders15/111
HeadacheNervous system disorders15/111
ThirstGeneral disorders14/111
HypokalaemiaMetabolism and nutrition disorders13/111

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tolvaptan
Mean64.6 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan
Female56
Male55
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010 Apr;21(4):705-12. doi: 10.1681/ASN.2009080857. Epub 2010 Feb 25. Erratum In: J Am Soc Nephrol. 2010 Aug;21(8):1407. PubMed 20185637 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 20, 2015
Start
May 2004
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Jan 21, 2016
Last update
Jan 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02449044
Responsible party
Sponsor
First posted
May 20, 2015
Start date
May 2004
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Jan 21, 2016
Last update
Jan 21, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion